Leprosy as requiring prolonged compulsory segregation

Where in the source: The 20th Century, 1945–Today

NPS describes the 1946 treatment transition and 1969 abolition of forced-quarantine laws. It does not supply the 1949 date or the complete administering-body sequence, which the legislative and archival sources provide.

Where in the source: Treatment and policy history

The official history links effective sulfone treatment to the long transition before legal repeal in 1969; the archival study supplies the specific 1949 administrative transfer and narrowed quarantine rules.

Where in the source: Section 1

The legislative account documents forced removal and isolation and distinguishes the 1949 and 1969 milestones. It is not used as a complete history of the intervening administrative controls.

Where in the source: Brief History; Kalaupapa Transition Timeline, 1969

The state health department records the 1969 lifting of the isolation order and repeal of segregation provisions, together with continued care and residence guarantees for former patients.

Where in the source: Printed pp. 548–549

The 1985 NPS study identifies the Board of Hospitals and Settlement, its abolition on 1 July 1949, and transfer of the program to the territorial Board of Health's Division of Hospitals and Settlement.

Where in the source: Printed pp. 527–528, 548–549, 564, 567

The study documents routine therapy, the 1949 administrative and quarantine changes, later controlled travel and the 1969 legal change. It supports a phased mechanism rather than uniform confinement through the whole interval.

Where in the source: Printed pp. 564, 567–568

The study describes increasing travel freedom under health-department controls, freedom to leave after 1969 and residents' continuing memories of forced isolation and family separation. It does not imply one uniform experience.

Where in the source: Printed pp. 548–549, 564, 567

The archival chronology distinguishes the 1949 operational reforms from the 1969 end of the legal isolation regime.

Where in the source: Historical Background

This official institutional history describes the regional sanitarium model and later domiciliary-care transition. It supplies context, not proof of the national statutory carriers named directly in Republic Act No. 753.

Where in the source: Section 1, amended sections 1058 and 1061–1063

The statute assigns diagnostic and transfer duties, creates reporting and anti-concealment rules, and authorizes institutions. It documents legal machinery, not the measured frequency of enforcement.

Where in the source: Section 2

Congress's 1966 policy declaration acknowledges that prolonged confinement severed connections with homes and families, left dischargeable patients jobless and caused emotional insecurity. It does not document the 1952 machinery.

Where in the source: Rodriguez, printed p. 233

J. N. Rodriguez reported that Promin arrived in 1946 but initially had to be purchased by patients, Diasone reached only a limited number, and DDS became generalized in the leprosaria in 1952. This does not establish universal access.

Where in the source: Sections 1–2; approved 18 June 1964

The primary 1964 statute says people with leprosy are not to be confined in a leprosarium unless the disease requires institutional treatment and repeals the former control provisions.

Where in the source: Transmission; Treatment

Provides current clinical context for transmission and treatment while leaving historical sulfone timing to Rodríguez and the legal chronology to the statutes.

Where in the source: Section 1, amended sections 1058, 1063 and 1066

Republic Act No. 753 directly assigns functions to the Director of Health and Director of Hospitals. Its facilities form a distributed statutory system and are not presented as a third aggregate institution.

Where in the source: Section 1, amended sections 1058 and 1061–1062

Supports the mandatory-isolation, reporting and statutory anti-concealment bullets. The inspected provisions do not by themselves establish a criminal penalty.

Where in the source: Sections 1–2

Supports the 1964 transition to clinic, rural-health-unit or licensed-physician treatment while retaining institutional care when the disease stage required it.

Where in the source: Summary Version, pp. 9–12, 43–50

These sections identify the Minister and Ministry of Health and Welfare's responsibility within the continued national policy and examine the delayed repeal; the 1960 holding itself is the court's.

Where in the source: Summary Version, pp. 43–50

The committee analyzes how national law, administration, medical actors and sanatoria sustained the policy. This documents an institutional mechanism without asserting identical confinement for every person in every year.

Where in the source: Summary Version, pp. 56–63

The damage survey documents restrictions, separation, stigma and cumulative life injuries under compulsory segregation. Individual experiences varied, so the episode does not turn the survey into a universal biography.

Where in the source: Summary Version, pp. 9–12, 43–50

The report records the 1996 repeal and investigates why it was delayed. Repeal corrected the statutory framework, not the accumulated damage or all later discrimination.

Where in the source: Transmission; Treatment

Provides current clinical context for why blanket prolonged segregation is unnecessary after effective treatment; it is not evidence for Japan's historical adoption or repeal dates.